Clinical Trial

A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This early-stage study will look at a new mRNA vaccine that combines defenses against both seasonal flu and COVID-19 in terms of its safety and how it builds protection. Healthy adults aged 65 to 85 will receive different doses of this new vaccine, a standard flu vaccine, or COVID-19 vaccine. The study will assess any side effects or health issues, and additional blood samples will be collected at specific times to evaluate how well participants bodies build protection against the flu and COVID-19.
Protocol Amendment History 5 changes
critical Trial status changed: Active, Not Recruiting → Recruiting 2026-07-01
notable Enrollment reduced: 1475 -> 225 participants 2026-07-01
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-23
notable Enrollment increased: 225 -> 1475 participants 2026-06-23
notable Trial sites expanded: 2 -> 12 locations 2026-06-23
Trial Details
NCT Number NCT07464314
Lead Sponsor GlaxoSmithKline
Conditions Influenza, Human+COVID-19
Enrollment 225 participants
Start Date 2026-03-09
Primary Completion 2026-12-03 (estimated)
Study Completion 2027-06-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-30